Hagiwara A, Takahashi T, Ueda T, Nakagawa Y
Jpn J Cancer Res. 1987 Apr;78(4):405-8.
A new dosage form of mitomycin C (MMC-CH) was tested for toxicity and therapeutic efficacy against intraperitoneally inoculated cancer cells in mice. MMC-CH is a suspension comprising 7.16 mg/ml of activated carbon particles, 1 mg/ml of mitomycin C (MMC) and 20 mg/ml of polyvinylpyrrolidone in saline. The LD50 value determined by means of the Litchfield-Wilcoxon method after intraperitoneal administration was 2.29 times higher for MMC-CH than for MMC aqueous solution. Mice were inoculated intraperitoneally with 2 X 10(5) P388 leukemia cells and given an intraperitoneal injection of 10 to 1.25 mg/kg of MMC in the form of MMC-CH or MMC aqueous solution 24 hr after the inoculation. The median survival time was prolonged to 270.5%, 223.0% or 168.3% by MMC-CH at the dose equivalent to 10, 5 or 2.5 mg/kg of MMC, respectively, while it was prolonged to 182.7%, 139.6% or 155.4% by MMC aqueous solution at the dose of 5, 2.5 or 1.25 mg/kg of MMC, respectively, as compared with the median survival time in the non-treated group. MMC-CH prolonged the survival time to more than 120% as compared with the same dose of MMC given as MMC aqueous solution, and was less toxic.
对丝裂霉素C的一种新剂型（MMC-CH）进行了毒性测试以及针对小鼠腹腔接种癌细胞的治疗效果测试。MMC-CH是一种混悬液，在生理盐水中含有7.16mg/ml的活性炭颗粒、1mg/ml的丝裂霉素C（MMC）和20mg/ml的聚乙烯吡咯烷酮。腹腔给药后，采用Litchfield-Wilcoxon方法测定的MMC-CH的半数致死剂量（LD50）值比MMC水溶液高2.29倍。给小鼠腹腔接种2×10⁵个P388白血病细胞，并在接种后24小时以MMC-CH或MMC水溶液的形式腹腔注射10至1.25mg/kg的MMC。与未治疗组的中位生存时间相比，MMC-CH在相当于10、5或2.5mg/kg MMC的剂量下，中位生存时间分别延长至270.5%、223.0%或168.3%，而MMC水溶液在5、2.5或1.25mg/kg MMC的剂量下，中位生存时间分别延长至182.7%、139.6%或155.4%。与相同剂量的MMC水溶液相比，MMC-CH将生存时间延长至120%以上，且毒性较小。
